CN100522983C - Medical use of catalpol and its homologs - Google Patents
Medical use of catalpol and its homologs Download PDFInfo
- Publication number
- CN100522983C CN100522983C CNB2004100065905A CN200410006590A CN100522983C CN 100522983 C CN100522983 C CN 100522983C CN B2004100065905 A CNB2004100065905 A CN B2004100065905A CN 200410006590 A CN200410006590 A CN 200410006590A CN 100522983 C CN100522983 C CN 100522983C
- Authority
- CN
- China
- Prior art keywords
- catalpol
- group
- compd
- asthma
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to catalpol and the medical purpose of a derivative thereof. The catalpol and the derivative thereof can effectively treat and prevent asthma diseases, allergic rhinitis and other allergic disease symptoms. The catalpol and the derivative thereof can be prepared into different preparations with pharmaceutically acceptable excipient so as to treat and prevent asthma diseases, allergic rhinitis and other allergic disease symptoms. According to different proportioning, the catalpol, the derivative thereof and medicine for treating and preventing asthma diseases, allergic rhinitis and other allergic disease symptoms are prepared into a composition for treating the diseases. The catalpol and the derivative thereof can be prepared into different preparations with the pharmaceutically acceptable excipient.
Description
Invention field
The present invention relates to field of medicaments, a kind of composition and method of making the same that can effectively prevent and treat asthma and other irritated illness.
Background of invention
Asthma is the airway inflammation process based on the multiple inflammatory cell mediation of eosinophil, a kind of air flue chronic inflammatory diseases that chemical mediator that inflammatory cell discharges and chemokine and other multiple inflammatory mediator participate in.Bronchial asthma is chronic respiratory tract disease the most common in the world wide, and the conservative estimation whole world has the above asthma of suffering from of 100,000,000 people at least, in recent years, and because of its morbidity and mortality ratio all are taking advantage of a favourable situation of rising.Asthma has become serious public health problem and has received the very big concern of countries in the world.Therefore need provide the medicine and the method for the treatment of asthma effectively.
In the last thirty years, a large amount of development and researches has been carried out to the medicine of treatment asthma in the whole world.The medicine of the treatment asthma that has developed has β
2-3 adrenergic receptor agonists class, alpha-adrenergic aceptor antagonist class, aminophylline class, cholinergic receptor antagonist class, calcium ion antagonist class, potassium-channel agonist, glucocorticosteroid, cell membrane stability agent (Sodium Cromoglicate, Buddhist nun examine a meter sodium more), antihistamine drug, LTRA, platelet activation factor (PAF) antagonist, specific active immunotherapy agent, non-specific immunity therapeutical agent or the like.Asthma is the very complicated multi-factor disease of a kind of mechanism, is the diseases associated with inflammation that the many cells multimedium participates in.Above-mentioned these medicines (perhaps methods of treatment) mechanism of action single (to a kind of or two, three kind of medium, the factor, acceptor or passage work) result of treatment not obvious or oral invalid must the special pathway administration or side effect greatly can't life-time service.What generally adopt clinically at present also is that the most effective methods of treatment is to suck glucocorticosteroid (light moderate sucks Sodium Cromoglicate, the Buddhist nun examines a meter sodium more) anti-inflammatory for a long time, sucks β during asthma attack
2Bronchodilators such as-3 adrenergic receptor agonists, cholinergic receptor antagonist.These methods of treatment are to relieving asthma symptoms, and the quality of life of improving asthma patient has certain effect, but do not find that the M ﹠ M of asthma decreases.Reduce the M ﹠ M of asthma, the prognosis that improves asthma still lack effective means (Li Minghua etc., asthma, the People's Health Publisher, 1998, p2).
Summary of the invention
The present invention relates to Catalpol and the antasthmatic medicinal use of homologue antianaphylaxis thereof, they are natural plant composition, comprise Catalpol, Catalposide, Veronicoside mainly is present in the goatweed Picrorrhiza (as Rhizoma Picrorhizae (Picrorrhiza Scrophulariflora Pennell Yunnan Rhizoma Picrorhizae), India's Rhizoma Picrorhizae (P.kurroa), Veronica belongs to (as Herba Veronicae Undullatae (Herba Veronicae anagallis-aquaticae) (Veronica anagallis-aquatica)), in the plants such as Bignoniaceae plant (as Root of Asia Belltree (Radermachia sinica), Amphicome emodi Lindl Catalpa plant as).Catalpol and homologue thereof have the new purposes of treatment allergic asthma and other anaphylactic disease.They have when being used for such use that toxicity is little, determined curative effect and characteristics such as can take for a long time.
Catalpol and homologue thereof have following structure
R wherein
1Be H, OH or OR
4(R
4Be C
1～C
5Acyl group, C
1～C
5Alkyl, or glycosyl), R
2Be H, OH or OR
5(R
5Be C
1～C
5Acyl group, C
1～C
5Alkyl), R
3Be OH or OR
6(R
6Be acyl group).It also can be the following group that refers in particular to.
In the I formula:
R
1＝OH，R
2＝OH，R
3＝OH。The determined compd A of structural formula (I) is Catalpol (Catalpol) A by structural formula (A) representative.
R
1＝OH
R
3＝OH。The determined Compound C of structural formula (I) is the Kutkoside (Kutkoside) by structural formula (C) representative.
R
1=OH, R
2=OH,
The determined Compound D of structural formula (I) is the kutkin I (Picroside I) by structural formula (D) representative.
R
1＝OH，
R
3＝OH。The determined compound F 17-hydroxy-corticosterone of structural formula (I) is the Scutellarioside II by structural formula (F) representative.
The present invention relates to Catalpol and homologue thereof and they at different dosage form that pharmaceutically can received various excipient combinations, can treat and prevention of asthma disease, treatment and Ammonium Glycyrrhizate rhinitis with other, the medicine of supersensitivity illnesss such as anaphylaxis dermatosis is made composition with different proportionings, and makes different formulations with it in pharmaceutically acceptable various excipient combination and carry out practical application on to the treatment of the inflammatory diseases of respiratory immunity mediation, prevention.
The various dosage form of the pharmaceutical composition of Catalpol and homologue thereof comprise oral dosage form, the solution dosage of inhalation, injectable and infusion and local skin drug formulation.When using with inhalation or aerosol form, Catalpol and homologue thereof are used in combination with the dry powder that pharmaceutically acceptable carrier soln maybe can change into the form of aerosol.When being used for the treatment of immune-mediated inflammatory dermatosis, Catalpol and homologue thereof are used in combination with nontoxic, pharmaceutically acceptable topical vehicle.Catalpol and homologue thereof can with the treating asthma agent, as β
2-3 adrenergic receptor agonists, cholinergic receptor antagonist, aminophylline class, glucocorticosteroid, antihistamine drug etc. are used in combination.
Catalpol and homologue thereof are used to prevent and treat immune-mediated inflammatory diseases, particularly comprise the disease relevant with respiratory tract of asthma, and particularly relevant with chronic asthma replying by force and rhinallergosis.Therefore the present invention also provides the method for the treatment of immune-mediated inflammatory diseases, and this method comprises to the Catalpol and the homologue thereof that have immune-mediated inflammatory diseases patient with treatment effective dosage forms and dosage.
The dosage of Catalpol and homologue thereof among the present invention, because of patient's state, body weight, administering mode etc. different different.Such as administration 0.1～250mg/kg.d or 1-50mg/kg.d under non-oral situation, in the intramuscular, vein, intestines, 1～1000mg/kg.d or 5-200mg/kg.d under the oral situation.
The toxicity of Catalpol and homologue thereof is very little among the present invention.
The oral maximum dosage-feeding of Catalpol (A) acute toxicity test is 38.6g/kg, does not see animal dead; Intraperitoneal injection LD
50Be 12.65～16.51g/kg, intravenous administration LD
50Be 1.91～2.35g/kg.
The oral maximum dosage-feeding of catalposide (B) acute toxicity test is 42.5g/kg, does not see animal dead; Intraperitoneal injection LD
50Be 10.81～14.53g/kg, intravenous administration LD
50Be 1.16～1.63g/kg.
The oral maximum dosage-feeding of Picroside (C) acute toxicity test is 37.8g/kg, does not see animal dead; Intraperitoneal injection LD
50Be 12.10～15.10g/kg, intravenous administration LD
50Be 1.40～1.70g/kg.
The oral maximum dosage-feeding of kutkin I (D) acute toxicity test is 39.5g/kg, does not see animal dead; Intraperitoneal injection LD
50Be 9.87～13.55g/kg, intravenous administration LD
50Be 1.26～1.62g/kg.
The oral maximum dosage-feeding of Catalpa glycosides (E) acute toxicity test is 40.3g/kg, does not see animal dead; Intraperitoneal injection LD
50Be 11.85～15.50g/kg, intravenous administration LD
50Be 1.46～1.80g/kg.
The oral maximum dosage-feeding of Scutellariosid-II (F) acute toxicity test is 36.5g/kg, does not see animal dead; Intraperitoneal injection LD
50Be 11.25～14.51g/kg, intravenous administration LD
50Be 1.36～1.75g/kg.
Specific embodiment
With following embodiment the present invention is specified, but the present invention is not limited to the content that the following example comprises.Animal experiment of the present invention, selecting for use clinically has the FPL-670 of better curative effect to do positive control.
[embodiment one] allergic asthma test-Protalbinic acid aerosol sucks and draws the method for breathing heavily
Get 40 of 200-250g cavys, male and female half and half, prior to right rear leg outside intramuscular injection 4% albumin normal saline solution 0.2ml/ only, while abdominal injection 4% aluminum hydroxide gel 0.2ml sensitization.From sensitization second day, animal is divided into 8 groups at random: control group, FPL-670 group, compd A, B, C, D, E, F group, compd A, B, C, D, E, F be totally 6 groups of gastric infusions, FPL-670 group drug administration by injection, totally 14 days, after the last administration, animal is put in the airtight bell glass, after treating peace and quiet, start air compressor, constant voltage with 53kPa (400mmHg) sprayed into 3.5% Protalbinic acid physiological saline 30 seconds, observed the number of animals that cavy latent period of panting property tic occurs and takes place to twitch in the 6min.
Table 1 Compound I is drawn the influence of breathing heavily to the Protalbinic acid cavy
Annotate: compare * P＜0.05, * * P＜0.01 with the blank group
Table 1 result shows, compare with control group, in the latent period (P＜0.05) of the cavy asthma that compd A, B, C, D, E, F group 50mg/kg dosage energy significant prolongation Protalbinic acid cause, the 50mg/kg oral dosage is suitable with the effect of FPL-670 50mg/kg injected dose.Test shows that compd A, B, C, D, E, F have significant antiasthmatic effect.
[embodiment two] I allergic reaction type 1-passive cutaneous anaphylaxis tests (PCA)
The rat body is divided into 8 groups at random by heavy: blank group, FPL-670 group, compd A, B, C, D, E, F group, 10/group, male and female half and half.Preventive administration is adopted in test, 6 groups of gastric infusions such as compd A, B, C, D, E, F, and FPL-670 group drug administration by injection, successive administration is 14 days before antigen is attacked.
Antiserum Preparation: with four sole injections of above-mentioned Snakegourd Root aluminium hydroxide suspension, every sole injection 0.1ml is total to 0.4ml.10-15 days maturations, and the about 10ml of eyeball bloodletting with the centrifugal 15min of 3000 commentaries on classics/min, gets upper serum and promptly gets antiserum(antisera).
Passive sensitization of skin: will test and respectively organize the rat back depilation, 2 points are respectively got apart from center line 1.5cm in the backbone both sides, every some interval 2cm, the about 1 * 1cm of area
2, totally 4 points.In skin of back, inject sero-fast different extent of dilution (1:30 1:40) respectively.Carrying out quantitative corresponding antigens behind the 48h attacks.The tail vein injection Snakegourd Root adds AZO-blue solution 1mg/kg, sacrificed by decapitation behind the 30min.
Observation index: the sero-fast local skin reaction of intradermal injection, and measure the locus coeruleus diameter (cm) that AZO-blue is oozed out.Calculate PCA and suppress percentage (%).
Table 2 Compound I is to the influence of P of Rats CA reaction
Annotate: compare * P＜0.05 * * P＜0.01 with the blank group
The result can find out in the table 2, and compd A, B, C, D, E, F group 50mg/kg compare with the blank group when antiserum(antisera) extent of dilution 1:30, can significance suppress locus coeruleus formation (P＜0.05P＜0.01).When extent of dilution 1:40, compd B, C, E still have the restraining effect (P＜0.05) of significance.Test-results shows that compd A, B, C, D, E, F have significant inhibitory effect to I allergic reaction type-PCA reaction.
The test of [embodiment three] I allergic reaction type 2-mast cell degranulation
40 SD rats are divided into 8 groups at random by body weight: blank, Sodium Cromoglicate, compd A, B, C, D, E, F organize 50mg/kg.d, every group 10, male and female half and half, 1 time/d of administration, 6 groups of 50mg/kg gastric infusions such as compd A, B, C, D, E, F, FPL-670 group 50mg/kg drug administration by injection, successive administration 14 days.The anti-ovalbumin serum 0.1-0.2ml of rat head subcutaneous injection 1:5 dilution, behind the 48h, the blue solution of tail vein injection 1mg Protalbinic acid ivens is attacked.Attack back 30min with sacrifice of animal, peel off skin of head, take off skull, put into 95% Ethanol Treatment 1h, put into anhydrous methanol and spend the night.After mastocyte was handled with 0.18% toluylene red, the flowing water flushing was fixed on the little plank with the side of a pin with skull, carefully peels off periosteum with tweezers, is deployed on the slide glass drying, sealing.Scale microscopically direct viewing is housed in eyepiece, selects 2-3 higher zone of mastocyte density, calculate every mm
2The mastocyte number.And under high power lens, mastocyte is observed, mastocyte is divided into takes off particle and do not take off particle two classes, calculate the percentage of cell degranulation.
Table 3 Compound I is to the degranulated influence of rat hypertrophy cell
| Group | Number of animals (only) | Dosage (mg/kg) | Take off particle percentage (%) |
| The blank group | 10 | -- | 95.6±9.4 |
| Sodium Cromoglicate | 10 | 50 | 84.3±8.7* |
| Compd A | 10 | 50 | 82.7±11.6* |
| Compd B | 10 | 50 | 82.8±8.7** |
| Compound C | 10 | 50 | 79.6±9.6** |
| Compound D | 10 | 50 | 81.5±10.6** |
| Compd E | 10 | 50 | 83.4±11.2* |
| Compound F 17-hydroxy-corticosterone | 10 | 10 | 84.6±9.6* |
Annotate: compare with the blank group: * P＜0.05 * * P＜0.01
Table 3 result can find out, compares with the blank group, and compd A, B, C, D, E, F group 50/kg have significant inhibitory effect (P＜0.05, * * P＜0.01) to mast cell degranulation.Show that compd A, B, C, D, E, F have significant inhibitory effect to the I allergic reaction type.
Ear swelling test due to [embodiment four] IV allergic reaction type-haptens (DNCB)
48 mouse are divided into 8 groups at random by body weight: blank, Sodium Cromoglicate, compd A, B, C, D, E, F group, every group 12, male and female half and half, 1 time/d of administration, 6 groups of 50mg/kg.d gastric infusions such as compd A, B, C, D, E, F, FPL-670 group 50mg/kg.d intraperitoneal injection, successive administration 10d.Give mouse back subcutaneous injection 0.02ml with 1%2,4-dinitrochlorobenzene (DNCB) acetone soln, sensitization is applied to auris dextra with 1%DNCB glycerine solution 0.03ml after 10 days and attacks, and left ear is coated with the equivalent glycerine solution and compares; Mouse is put to death in cervical vertebra dislocation behind the 16h, cuts left and right sides auricular concha, take off diameter 9mm with punch tool two.To get about two auricles weigh, with the difference of left and right sides auricle weight as the swelling degree.
The influence of the mice ear that table 4 Compound I causes DNCB
Annotate: compare with the blank group: * P＜0.05 * * P＜0.01
Table 4 result shows, compares with the blank group, and the mice ear that Rhizoma Picrorhizae glucoside II 40,80mg/kg cause DNCB has significant inhibitory effect (P＜0.05, P＜0.05).Show that compd A, B, C, D, E, F have remarkable restraining effect to this type of tardy parasexuality reaction.
[embodiment five] cellular immune function test-sheep red blood cell (SRBC)s (SRBC) cause the foot swelling of tardy property
48 of NIH mouse are pressed the body weight random packet: blank, Sodium Cromoglicate, compd A, B, C, D, E, F group, 12/group, male and female half and half.6 groups of 80mg/kg.d gastric infusions such as compd A, B, C, D, E, F, FPL-670 group 80mg/kg.d intraperitoneal injection, administration 1 time/day, administration continued administration 5 days in 5 days before the sensitization to sensitization, and successive administration is 10 days altogether.After the sensitization 5 days, 0.05ml/ sensitization of mouse neck s.c5% sheep red blood cell (SRBC) (SRBC).Right foot pad s.c5%SRBC 0.02ml attacks after 6 days.Left side foot injection equivalent physiological saline compares.Put to death animal behind the last administration 50min.Cutting two foots from the ankle joint position weighs.Obtain the weight difference of two foots, calculate paw swelling.
The influence of the mouse foot swelling that table 5 Compound I causes SRBC
Annotate: compare with the blank group: * P＜0.05
Table 5 result shows, compares with the blank group, and the mouse foot swelling that compd A, B, C, D, E, F group 80mg/kg cause SRBC has significant inhibitory effect (P＜0.05).Show that compd A, B, C, D, E, F have remarkable restraining effect to this cell immune response.
Claims (1)
1, compound Catalpol, catalposide, Kutkoside, kutkin I or the Catalpa glycosides application in the pharmaceutical composition of preparation treatment asthma or allergic rhinitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100065905A CN100522983C (en) | 2004-03-11 | 2004-03-11 | Medical use of catalpol and its homologs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100065905A CN100522983C (en) | 2004-03-11 | 2004-03-11 | Medical use of catalpol and its homologs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1666992A CN1666992A (en) | 2005-09-14 |
| CN100522983C true CN100522983C (en) | 2009-08-05 |
Family
ID=35038298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100065905A Expired - Fee Related CN100522983C (en) | 2004-03-11 | 2004-03-11 | Medical use of catalpol and its homologs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100522983C (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2610211C (en) | 2005-05-30 | 2012-02-21 | Hyeong Kyu Lee | Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
| US8455541B2 (en) | 2005-05-30 | 2013-06-04 | Korea Research Institute Of Bioscience And Biotechnology | Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
| KR20060125499A (en) * | 2005-05-30 | 2006-12-06 | 한국생명공학연구원 | Pharmaceutical composition comprising the catalpol derivatives isolated from the extract of pseudolysimachion longifolium having anti-inflammatory, anti-allergic and anti-asthmatic activity |
| CN102633849B (en) * | 2011-09-23 | 2016-06-15 | 江苏省中国科学院植物研究所 | The preparation method of iridoid Chinese catalpa glycosides and anticancer purpose |
| CN103494938B (en) * | 2013-09-27 | 2015-01-07 | 张玲 | Application of catalpol in preparing medicine for treating oral ulcer |
| KR101715676B1 (en) * | 2015-06-17 | 2017-03-13 | 영진약품공업주식회사 | a novel compound (KS 513) isolated from the extract of Pseudolysimachion rotundum var. subintegrum and the composition comprising the same as an active ingredient for preventing or treating allergy disease, inflammatory disease, asthma or chronic obstructive pulmonary disease |
| CN105198941A (en) * | 2015-09-21 | 2015-12-30 | 济南同生生物医药科技有限公司 | Aluminum oxide pressurized column chromatography preparation of 6'-O-trans cinnamyl catalpa alcohol |
| CN105820200B (en) * | 2016-04-14 | 2018-05-08 | 安徽省逸欣铭医药科技有限公司 | A kind of catalpol derivatives and its preparation method and application |
| CN107739398A (en) * | 2017-10-19 | 2018-02-27 | 焦作大学 | A kind of propionating catalpol derivatives and its preparation method and application |
| CN109734759B (en) * | 2019-01-10 | 2022-05-10 | 上海中医药大学 | Catalpol derivative and application thereof |
| CN109806271B (en) * | 2019-02-11 | 2020-06-26 | 牡丹江医学院 | Pharmaceutical composition for treating allergic dermatitis and preparation thereof |
-
2004
- 2004-03-11 CN CNB2004100065905A patent/CN100522983C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1666992A (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100522983C (en) | Medical use of catalpol and its homologs | |
| JPH07507054A (en) | Topical composition containing hyaluronic acid and NSAIDS (non-steroidal anti-inflammatory drugs) | |
| CN104547826B (en) | Galangal rhizome extract treats the medical usage of dysmenorrhoea | |
| WO2019206159A1 (en) | Use of chlorogenic acid and composition thereof in preparation of medicament for treating sarcoma | |
| JPS5841821A (en) | Antiinflammatory composition showing minimized gastric injury | |
| US11357814B2 (en) | Application of Sarcococca vagans, Chinese medicinal ointment for treating skin disease, preparation method and application thereof | |
| CN1468601A (en) | Picroside-II as one new medicine for preventing and treating allergic and inflammatory diseases | |
| JP2013049729A (en) | Pharmaceutical composition | |
| WO2013060275A1 (en) | Application of albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer | |
| JP3987501B2 (en) | Pharmaceutical composition | |
| Girish et al. | Antiulcer activity of aqueous extract of leaves of Scoparia dulcis (Linn.) in rats | |
| CN107638497B (en) | Traditional Chinese medicine composition for treating venomous snake bite and preparation method and application thereof | |
| EP2043669A2 (en) | Compositions and methods for treating and preventing gastro esophageal reflux disease | |
| CN100349589C (en) | Medical application of rehmannia root extractive in resisting asthma and allergy | |
| JP2723473B2 (en) | Uses of sulfated saccharides | |
| JP4253161B2 (en) | Topical agent for treatment of allergic diseases | |
| CN104147007B (en) | A kind of for analgesic medical composition and its use | |
| CN1332675C (en) | Medicine application of catalpa and extractive for anti allergic disease | |
| CN102366484A (en) | Pharmaceutical composition for treating herpes zoster and preparation method thereof | |
| CN115990218B (en) | Yao medicine composition with function of improving knee osteoarthritis joint, and preparation method and application thereof | |
| JPH0710752A (en) | Novel medicinal composition for treating allergic and autoimmune diseases | |
| JP5800485B2 (en) | Composition for inhibiting nasal secretion | |
| CN1465389A (en) | Daqinglong decoction and preparation thereof | |
| CN112438981A (en) | Application of madecassic acid in preparation of medicine for preventing or treating ulcerative colitis | |
| CN117797168A (en) | Allergen-isolated nasal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090805 Termination date: 20120311 |